Cardiac effects of anthracycline treatment and their implications for aeromedical certification

Aviation Space and Environmental Medicine

Volumn 74, Issue 9, 2003, Pages 1003-1008

  Evans, Sally A ^a   Cooke, John N C ^b  

^a Civil Aviation Authority   (United Kingdom)

^b NONE

Author keywords

Adverse effects; Aerospace medicine; Anthracyclines; Heart diseases

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; THALLIUM;

ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AEROSPACE MEDICINE; AGED; AIRPLANE PILOT; ARTICLE; AUTOPSY; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; DRUG FATALITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EXERCISE TEST; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE FIBROSIS; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HODGKIN DISEASE; HUMAN; LICENSING; MALE; PHYSICAL EXAMINATION;

ADULT; AEROSPACE MEDICINE; AIR AMBULANCES; ANTHRACYCLINES; ARRHYTHMIA; CARDIOVASCULAR SYSTEM; CERTIFICATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY; EXERCISE TEST; FEMALE; GREAT BRITAIN; HEART BLOCK; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0041836234     PISSN: 00956562     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Barzilay J, Froom P, Ribak J, et al. Predictive value of premature ventricular contractions on the resting electrocardiogram for ventricular arrhythmias on 24 hour monitoring in asymptomatic young adults. Aviat Space Environ Med 1987; 58:80-2.
2. Billingham ME, Bristow MR, Glatstein E, et al. Adriamycin cardiotoxicity: Endomyocardial biopsy evidence of enhancement by irradiation. Am J Surg Pathol 1977; 1:17-23.
3. Bjerregaard P, Sorensen K, Molgaard H. Predictive value of ventricular premature beats for subsequent ischaemic heart disease in apparently healthy subjects. Eur Heart J 1991; 12:597-601.
4. Bristow MR, Billingham ME, Mason JW, Daniels JR. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 1978; 62:873-9.
5. British National Formulary. London: British Medical Association; 1999; 38:375-393.
6. Bu'lock FA, Mort MG, Oakhill A, Martin RP. Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and pathophysiology. Br Heart J 1995; 73:340-50.
7. Campbell RWF. Ventricular rhythm disturbances in the normal heart. Eur Heart J 1992; Suppl H:139-43.
8. Couch RD, Loh KK, Sugino J. Sudden cardiac death following adriamycin therapy. Cancer 1981; 48:38-9.
9. Evans S. Fitness to fly after chemotherapy [Dissertation]. London: Royal College of Physicians, Faculty of Occupational Medicine; 2000:12-63.
10. Folarin VA, Fitzsimmons PJ, Kruyer WB. Holter monitor findings in asymptomatic male military aviators without structural heart disease. Aviat Space Environ Med 2001; 72:836-8.
11. Froelicher VF, Thompson AJ, Wolthus R, et al. Angiographic findings in asymptomatic crewmen with electrocardiographic abnormality. Am J Cardiol 1977; 39:32-8.
12. Goorin AM, Chauvenet AR, Perez-Atayde AR, et al. Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediatr 1990; 116:144-7.
13. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998; 25(suppl 10):72-85.
14. Hale JP, Lewis IJ. Anthracyclines: cardiotoxicity and its prevention. Arch Dis Child 1994; 71:457-62.
15. Hellman K. Preventing the cardiotoxicity of anthracyclines by dexrazoxane. Br J Med 1999; 319:1085-6.
16. Krischer JP, Epstein S, Cuthbertson DD, et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The pediatric oncology group experience. J Clin Oncol 1997; 15:1544-52.
17. Larsen RL, Jakacki RI, Vetter VL, et al. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol 1992; 70:73-7.
18. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukaemia in childhood. N Engl J Med 1991; 324:808-15.
19. Lipshultz SE, Colan SD, Walsh EP, et al. Ventricular tachycardia and sudden unexplained death in late survivors of childhood malignancy treated with doxorubicin. Pediatr Res 1990; 27:145A.
20. Lipshultz SE, Sallan SE. Cardiovascular abnormalities in long-term survivors of childhood malignancy. J Clin Oncol 1993; 11:1199-203.
21. Maguire JJ QC. Determination in fatal accident inquiry number B475/97. Falkirk, UK: Sheriff Clerk of Tayside Central and Fife; 1997.
22. Makinen L, Makipernaa A, Rautonen J, et al. Long-term cardiac sequelae after treatment of malignant tumour with radiotherapy or cytostatics in childhood. Cancer 1990; 65:1913-7.
23. Postma A, Bink-Boelkens MTE, Beaufort-Krol GCM, et al. Late cardiotoxicity after treatment for a malignant bone tumour. Med Pediatr Oncol 1996; 26:230-7.
24. Scott O, Williams GJ, Fiddler GI. Results of 24 hour ambulatory monitoring of electrocardiogram in 131 healthy boys aged 10-13 years. Br Heart J 1980; 44:304-8.
25. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996; 125:47-58.
26. Siveski-Iliskovic N, Hill M, Chow DA, Singal PK. Probucil protects against Adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation 1995; 91:10-5.
27. Sorensen K, Levitt G, Bull C, et al. Anthracycline dose in childhood acute lymphoblastic leukaemia: issues of early survival versus late cardiotoxicity. J Clin Oncol 1997; 15:61-8.
28. Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol 1995; 24:352-61.
29. Steinherz LJ, Steinherz PG, Tan CTC, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266:1672-7.
30. Valagussa P, Zambetti M, Biasi S, et al. Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer. Ann Oncol 1994; 5:209-16.
31. Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 1992; 19:670-86.